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SUMMARY
Multiple myeloma bone disease is devastating for patients and a major cause of morbidity. The disease leads
to bone destruction by inhibiting osteoblast activity while stimulating osteoclast activity. Recent advances in
multiple myeloma research have improved our understanding of the pathogenesis of multiple myeloma-
induced bone disease and suggest several potential therapeutic strategies. However, the effectiveness of
some potential therapeutic strategies still requires further investigation and optimization. In this paper, a re-
cently developed mathematical model is extended to mimic and then evaluate three therapies of the disease,
namely: bisphosphonates, bortezomib and TGF-β inhibition. The model suggests that bisphosphonates and
bortezomib treatments not only inhibit bone destruction, but also reduce the viability of myeloma cells. This
contributes to the current debate as to whether bisphosphonate therapy has an anti-tumour effect. On the
other hand, the analyses indicate that treatments designed to inhibit TGF-β do not reduce bone destruction,
although it appears that they might reduce the viability of myeloma cells, which again contributes to the cur-
rent controversy regarding the efﬁcacy of TGF-β inhibition in multiple myeloma-induced bone disease.
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1. INTRODUCTION
Multiple myeloma (MM), a haematological malignancy developed in the bone marrow, is the most
common cancer involving bone and the second most prevalent cancer involving blood cells [1, 2].
Bone disease is a major complication of MM and is a signiﬁcant cause of morbidity in MM patients.
Up to 60% of MM patients suffer a fracture during the course of the disease, and MM induced bone
destruction rarely heals. Recent research into MM bone disease has revealed that the interaction be-
tween MM cells and the bone microenvironment plays an important role in the development of the
condition, and a ‘vicious cycle’ of myeloma development and bone destruction is established [2–4].
Currently, several therapies are proposed to treat MM-induced bone disease including
bisphosphonates, bortezomib and TGF-β inhibition [2, 5, 6]. Bisphosphonate treatments target high
turnover skeletal sites, binding to the mineralized bone matrix within these sites [7–9]. After their
internalization by bone-resorbing osteoclasts, bisphosphonates inhibit further osteoclast activity
and bone resorption by suppressing the differentiation of osteoclast precursors into mature osteo-
clasts, promoting osteoclast apoptosis and disrupting osteoclast function [8, 9]. Although
bisphosphonates are already a ﬁrst-line treatment for MM-induced bone disease [7, 10], further
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investigation is required to determine whether bisphosphonates have an anti-tumour effect. Several
preclinical and clinical studies suggest that bisphosphonates may either have a direct or indirect
anti-tumour effect [11–18]. However, other studies provide contradictory evidence and suggest that
bisphosphonates do not improve patient mortality [19–21].
Suppression of bone-forming osteoblasts, which can occur from the blockade of the differentia-
tion of osteoblast precursors into mature osteoblasts, promotes the growth of myeloma cells as well
as bone destruction through supporting the production of anti-apoptotic factors and growth factors
for MM cells [2, 22]. Thus, it is suggested that stimulation of osteoblast differentiation may reduce
tumour burden and bone destruction in MM patients [2, 23]. Bortezomib, a boron-containing com-
pound with the potential of enhancing osteoblast proliferation and bone formation in MM patients,
has therefore been proposed as a potential therapeutic for MM-induced bone disease [24, 25].
TGF-β is reported to contribute to the progression of MM-induced bone disease [5]. It is released
with bone resorption and stimulates the production of osteoblast progenitors but inhibits the differ-
entiation of mature osteoblasts. It therefore suppresses bone formation and indirectly promotes the
progression of MM cells (immature osteoblast cells facilitate the growth and survival of MM cells,
while mature cells enhance apoptosis of MM cells). Thus, the suppression of TGF-β is proposed as
a new approach to treat MM-induced bone disease [5]; however, some controversies still exist, and
further investigation is required to conﬁrm its potential.
In the paper, a mathematical model we described previously [3] was extended to simulate these
three different strategies and determine their efﬁcacies in MM (Tables I and II).
2. MODEL DEVELOPMENT
The mathematical model which simulates the pathogenesis of MM-induced bone disease consists of
the following key equations [3]:
dOBp
dt
¼ DOBu πTGF βact;OBu OBu  DOBp π
TGF β
rep;OBp
πVCAM1rep;OBp OBp (1)
dOBa
dt
¼ DOBp πTGF βrep;OBp πVCAM1rep;OBp OBp  AOBa πVCAM1act;OBa OBa (2)
dOCa
dt
¼ DOCp πRANKLact; OCp OCp  π
TGF β
act;OCa
AOCa OCa (3)
dMM
dt
¼ DMM  πIL6act; MM πVCAM1act; MM MM 1
MM
MMmax
 
 AMM πSLRPsrep;MM MM (4)
dBV
dt
¼ Kres·OCa þ KformOBa (5)
where OBp, OBa, OCa,MM and BV are the populations of osteoblast precursors, active osteoblasts, ac-
tive osteoclasts, active MM cells and bone volume respectively, and dOBpdt is the variation of OBp with
time, for example. Eqs. (1) to (5) describe the temporal variations in concentrations of OBp, OBa, OCa,
MM and BV respectively. ‘Hill functions’ are used to represent the cellular interaction via the single
ligand to receptor binding, and are denoted by π functions. The deﬁnitions of the π functions in the
model equations above, and the deﬁnitions and values of the model parameters are lengthy and de-
scribed in detail in the work of [3] (Open Access), but are summarized here for convenience. Table III
contains the deﬁnitions and values of the model parameters. Any unknown parameters (i.e. those pa-
rameters where experimental data are unavailable or those which have no direct biological meaning)
are calculated via a genetic algorithm (GA) as indicated in Table III, and described in detail in [3].
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Brieﬂy, because a parameter may be directly or indirectly related with one or more of the initial values
of cell concentrations (listed in Table IV), e.g. DOBu and DOBp involve experimental data of the initial
concentration of OBp in Table IV, these initial values are set as targets for the parameter ﬁtting. The
calculation of the model parameters is then achieved by trying different values in a domain and then
selecting those that provide the best ﬁt with the corresponding experimental data. Based on these
values, the remaining unknown model parameters are then calculated according to relevant experimen-
tal data through the genetic algorithm. Thus the GA approach effectively considers all possible com-
binations of the unknown parameters and predicts the optimal values, as described in [3]. This takes
many hours on a powerful PC, potentially considering billions of combinations in its search for the op-
timum set. The simulation was carried using the Matlab computational software package (v7.7.0,
Mathworks, Natick, USA).
2.1. Modelling bisphosphonates treatment
Bisphosphonate treatments inhibit bone resorption by suppressing the differentiation of mature os-
teoclasts as well as promoting the apoptosis of osteoclasts. Eq. (3) describes the variation of oste-
oclasts with time for patients with MM-induced bone disease. In order to investigate the efﬁcacy
of biphosphonate treatments against the disease, a parameter F.Bi, representing the degree that
the bisphosphonates inhibit bone resorption, is added in Eq. (3), and the new equation is as follows:
dOCa
dt
¼ DOCp πRANKLact; OCp OCpF:Bi π
TGF β
act;OCa
AOCa OCa 1þ 1 F:Bið Þð Þ: (6)
The value of parameter F.Bi is in the range of [0, 1] and is negatively correlated to the concen-
tration of bisphosphonate during the treatment, thus a small value of F.Bi corresponds to a large
Table I. Deﬁnitions of the π functions. See Table II for
deﬁnitions of RANKL, OPG, TGF-β, PTH, IL6, SLRPs, VLA4
and VCAM1.
πTGF βact;OBu ¼ TGF βKD1;TGF βþTGF β
πTGF βrep;OBp ¼ 11þ TGF β=KD2;TGF βð Þ
πTGF βact;OCa ¼ TGF βKD3;TGF βþTGF β
πRANKLact; OCp ¼ RANKLKD;RANKLþRANKL
πIL6act; MM ¼ IL6IL6þKD;IL6;MM;act
πVCAM1act; MM ¼ VCAM1VCAM1þKD;VCAM1;MM;act
πVCAM1rep; OBp ¼ 11þVCAM1=KD;VCAM1;OBp ;rep
πVCAM1act; OBa ¼ VCAM1VCAM1þKD;VCAM1;OBa ;act
πSLRPsrep;MM ¼ 11þ SLRPs=KD;SLRPs;MM;repð Þ
πPTHact;RANKL ¼ PTHKD1;PTHþPTH
πPTHrep;OPG ¼ 11þ PTH=KD2;PTHð Þ
πIL6act; RANKL ¼ IL6IL6þKD;IL6;RANKL;act
πVLA4act;IL6 ¼ VLA4VLA4þKD;VLA4;IL6;act
πTGF βact;IL6 ¼ TGF βTGF βþKD;TGF β;IL6;act
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dosage of bisphosphonate, which would produce a corresponding decrease in the differentiation rate
of mature osteoclasts and thus osteoclast apoptosis is stimulated. For example, when F.Bi is set as
0.7, the differentiation rate of active osteoclasts is decreased to 70% (0.7), while the apoptosis of
osteoclasts increases by 30% (1F.Bi).
2.2. Modelling bortezomib treatment
Bortezomib stimulates osteoblast proliferation and bone formation in MM patients, which can po-
tentially inhibit the growth of myeloma cells as well as bone destruction. Eq. (2) represents the tem-
poral variation of osteoblasts under the condition of MM-induced bone disease. In order to simulate
bortezomib treatment, a parameter F.Bo, which represents the degree by which osteoblast differen-
tiation is promoted, is introduced to extend Eq. (2), and the new equation is as follows:
dOBa
dt
¼ DOBp πTGF βrep;OBp πVCAM1rep;OBp OBpF:Bo AOBa πVCAM1act;OBa OBa: (7)
The value of parameter F.Bo is in the range of (1, + ∞), and is positively related to the dosage of
bortezomib during the treatment. For example, when F.Bo is set to 2.0, osteoblast activity is in-
creased two-fold.
2.3. Modelling TGF-β inhibition treatment
TGF-β stimulates the production of osteoblast progenitors while inhibiting the differentiation of
mature osteoblasts as shown in Eqs. (1) and (2), and thus the inhibition of TGF-β indirectly sup-
presses the progression of MM cells, because immature osteoblast cells facilitate the growth and
survival of MM cells, while mature cells enhance apoptosis of MM cells. In addition, TGF-β can
Table II. Deﬁnitions of the concentrations of RANKL, OPG,
TGF-β, PTH, IL6, SLRPs, VLA4 and VCAM1. (RANKL,
receptor activator of nuclear factor kappa-B ligand; OPG,
osteoprotegerin; TGF-β, transforming growth factor-beta; PTH,
parathyroid hormone; IL-6, interleukin-6; SLRP, small leucine-
rich proteoglycan; VLA-4, very late antigen-4; VCAM-1,
vascular cell adhesion molecule 1).
RANKL PRANKL;dþβRANKLOBp
1þKA;OPG OPGþKA;RANK RANKð Þ βRANKL
RRANKL πIL6
act;RANKL
πPTH
act;RANKL
þDRANKL
 
OPG
POPG;dþβOPGOBa πPTHrep;OPG
βOPG OBa πPTHrep;OPG
OPGmax
þDOPGþDOPG;MM MM
 
TGFβ α·Kres ·OCaþSTGF β
D ̃TGF β
PTH βPTHþPPTH;d tð Þ
D ̃PTH
IL6
PIL6;dþβIL6OBu πTGFact;IL6πVLA4act;IL6
βIL6 OBu πTGFact;IL6 π
VLA4
act;IL6
IL6max
þDIL6
 
SLRPs βSLRPs OBaþPSLRPs;d tð ÞβSLRPs OBa
SLRPsmax
þD ̃SLRPsð Þ
VLA4 PVLA4;dþβVLA4·MM
1þKA;VCAM1·VCAM1totð Þ βVLA4RVLA4þDVLA4
 
VCAM1 VCAMtot1þKA;VCAM1VLA4
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Table III. Deﬁnitions and values of model parameters used in the model of MM-induced bone disease.
(GA=genetic algorithm).
Parameters Description Value
DOBu Differentiation rate of osteoblast progenitors 3.24e + 2/day (estimated)
DOBp Differentiation rate of osteoblast precursors 3.67e 1/day (estimated)
AOBa Rate of elimination of active osteoblasts 3.00e 1/day [32]
DOCp Differentiation rate of osteoclast precursors 1.73e 1/day (estimated)
AOCa Rate of elimination of active osteoclasts 1.20/day [32]
KD1,TGFβ Activation coefﬁcient related to growth factors
binding on OBu
4.28e 4 pM (calculation by GA)
KD2,TGFβ Repression coefﬁcient related to growth factors
binding on OBp
2.19e 4 pM (estimated)
KD3,TGFβ Activation coefﬁcient related to growth factors
binding on OCa
4.28e 4 pM [32]
KD1,PTH Activation coefﬁcient for RANKL production
related to PTH binding
2.09e + 1 pM (calculation by GA)
KD2,PTH Repression coefﬁcient for OPG production
related to PTH binding
2.21e 1 pM [32]
KD,TGFβ,IL6,act Half-maximal concentration of TGF-β on
promoting the production of IL-6
1.2e 4 pM (calculation by GA)
KD,IL6,RANKL,act Half-maximal concentration of IL6 on
promoting the production of RANKL
0.2 pM (calculation by GA)
KD,RANKL Activation coefﬁcient related to RANKL
binding to RANK
4.12e + 1 pM (estimated)
α TGF-β content stored in bone matrix 1.00 pM/% [32]
D ̃TGF β Rate of degradation of TGF-β 2.00e + 2/day [33]
βPTH Rate of synthesis of systemic PTH 9.74e + 2 pM/day [34]
D ̃PTH Rate of degradation of PTH 3.84e + 2/day [34]
βIL6 Rate of synthesis of IL6 per cell 1.20e + 7/day [35, 36]
DIL6 The degradation rate of IL6 4.99e + 1/day [37]
IL6max The maximum concentration of IL-6 8.04e 1 pM [38]
βOPG Minimum rate of production of OPG per active
osteoblast
5.02e + 6/day (estimated)
D ̃OPG Rate of degradation of OPG 4.16/day [39]
OPGmax Maximum possible OPG concentration 7.98e + 2 pM [40]
βRANKL Production rate of RANKL per cell 8.25e + 5/day (estimated)
D ̃RANKL Rate of degradation of RANKL 4.16/day [41]
RRANKL Maximum number of RANKL on the surface of
each osteoblastic precursor
3.00e + 6 [32]
RANK Fixed concentration of RANK 1.28e + 1 pM [32]
KA,OPG Association rate constant for RANKL binding
to OPG.
5.68e 2/pM [42]
KA,RANK Association rate constant for RANKL binding
to RANK.
7.19e 2/pM [42]
Kres Relative rate of bone resorption (normalized
with respect to normal bone resorption)
2.00e + 2%/(pMday) [43]
Kform Relative rate of bone formation (normalized
with respect to normal bone resorption)
3.32e + 1%/(pMday) (calculation by GA)
DMM MM proliferation controlled by IL-6 and
BMSC-MM adhesion
5.50e 2/day (estimated)
AMM Rate of elimination of active MM cells 2.00e 3/day [44]
MMmax Maximum possible MM cell concentration 1.98 pM [45]
KD,VCAM1,MM,act Half-maximal concentration of VLA-4 on
promoting the MM cells production
1.5667e 4/pM (calculation by GA)
KD,VLA4,IL6,act Half-maximal concentration of VLA 4VLA
4 on promoting the IL-6 production
1.88e + 4/pM (calculation by GA)
KD,IL6,MM,act Half-maximal concentration of IL-6 on
promoting the MM cells production
1.2151e 5 pM (calculation by GA)
KD,SLRPs,MM,rep Half-maximal concentration of SLRPs on
promoting the MM cells production
1.306e + 9 pM (calculation by GA)
(Continues)
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also promote the apoptosis of active osteoclasts as shown in Eq. (3). In the model of [3], the con-
centration of TGF-β is deﬁned as follows:
TGF β ¼ α·Kres·OCa þ STGF β
D̃TGF β
: (8)
The deﬁnitions and values of parameters in Eq. (8) are included in Table III. In order to examine
the potential of TGF-β inhibition treatment against MM-induced bone disease, a parameter F.T,
which describes the degree by which TGF-β is suppressed, is added into Eq. (8), so that the concen-
tration of TGF-β is updated to:
TGF β ¼ α·Kres·OCa þ STGF β
DT̃GF β
F:T (9)
where the value of parameter F.T is in the range of [0, 1], and is negatively related to the concentration
of TGF-β during the treatment; for example, an F.T value of 0.9 represents a reduction in TGF-β con-
centration to 90% of its normal value. As a result, model Eqs. (1) to (3), which contain TGF-β, are all
updated as well.
3. SIMULATION AND ANALYSIS
In all the following simulations, MM cell invasion is assumed to occur at day 51 with the different
interventions applied at day 301, once the MM and bone cell populations (OBp, OBa and OCp) have
stabilized again to their ﬁnal steady state value (to 578%, 293%, 199% and 249% of their values on
day 50). Because the actual relationships between parameters (F.Bi, F.Bo and F.T) and equivalent
Parameters Description Value
KD;VCAM1;OBp;rep Half-maximal concentration of VCAM-1 on
repressing the differentiation of OBp
1.4e 1 pM (calculation by GA)
KD;VCAM1;OBa;act Half-maximal concentration of VCAM-1 on
promoting the apoptosis of OBa
2.2e 1 pM (calculation by GA)
βVLA4 Rate of synthesis of VLA-4 per cell 2.04e + 6/day (estimated)
D ̃VLA4 Rate of degradation of VLA-4 1.5/day (estimated)
RVLA4 Maximum number of VLA-4 expressed on the
surface of MM cells
5.6e + 4 [46]
VCAM1tot Total concentration of VCAM-1 1.92 pM [46]
KA,VCAM1 The association rate for VLA-4 binding to
VCAM-1
8.3e 2/pM [47]
DOPG,MM The degradation rate of OPG by MM cells 4.16/(pMday) (estimated)
Table IV. The initial values of cell concentrations in the model.
Variables Description Values
OBu Uncommitted osteoblastic progenitors 3.27e 6 pM
OBp Osteoblast precursors 7.67e  4 pM
OBa Active osteoblasts 6.39e  4 pM
OCp Osteoclastic precursors 1.28e  3 pM
OCa Active osteoclasts 1.07e  4 pM
MM Active MM cells 3.26e  1 pM
Notes: MM cell concentration is at day 51; other cell concentrations are at day 1.
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drug dosages are currently not known, sample values of the parameters are investigated initially, to-
gether with further simulations to determine the sensitivity of the results to those values.
3.1. Simulation of bisphosphonates treatment
Figures 1 to 3 demonstrate how a bisphosphonate therapy, with F.Bi =0.7, might inﬂuence cell
concentrations and bone volume. Figure 1 shows a rapid increase in the population of MM cells
after their initial appearance at day 51. Treatment at day 301 then leads to a reduction in peak con-
centration of 16% by day 450 and a continued decrease until a stable value is achieved at day 1743
(not shown) of 4.43 times the original value (at day 51). Bone cell concentrations similarly increase
with the presence of the MM cells, but quickly return to a new stable state of typically 110% of their
normal values (i.e. before the invasion of the myeloma cells).
The ratio of bone cells, OBa:OCa, is predicted to decrease quickly to 80% of its initial value after
invasion of the MM cells (Figure 2), leading to a linear decrease in bone volume until application of
the bisphosphonate therapy at day 301 (Figure 3). At this point, the OBa:OCa ratio peaks but
quickly returns to 98% of its initial value, resulting in a signiﬁcant slowdown in bone destruction
as shown in Figure 3 after day 301.
Figures 4 to 6 show how MM cell concentration, bone volume and OBa:OCa ratio vary for sam-
ple F.Bi bisphosphonate inhibition values (of 0.7, 0.5 and 0.3) for the same treatment strategy. In
relation to their peak values at day 300, MM cell population decreases to 86.8%, 85.2% and 84%
(Figure 4), and OBa:OCa ratio increases to 123%, 134% and 144% when F.Bi is set to 0.7, 0.5
and 0.3 respectively (Figure 5). As illustrated in Figure 6, when F.Bi is set as 0.7, bone destruction
continues, although its rate is decreased markedly, because of the increased OBa:OCa ratio. How-
ever when F.Bi is set to 0.5 or 0.3, bone destruction is halted and bone volume begins to increase
again. Thus, the simulation results suggest that a smaller value of F.Bi produces a more signiﬁcant
inhibition of MM cell viability and bone destruction.
Figure 1. The variation of normalized cell concentrations with respect to their initial value during different
periods. Days 1 to 50: normal period; days 51 to 300: invasion of MM cells; and from day 301: intervention
with bisphosphonate therapy.
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3.2. Simulation of bortezomib treatment
Simulation results for the bortezomib therapy, applied at day 301 with F.Bo set to 2.2, are shown in
Figures 7 to 9, and again present the variations in cell concentrations, bone volume and the ratio of
OBa:OCa. The bortezomib causes a decrease in the population of MM cells (Figure 7), with con-
centrations of OBp, OBa and OCa also decreasing and approaching new equilibrium points by
day 450. For OBa and OCa these levels are near their initial values before the invasion of MM cells,
but OBp values are reduced by 51%. Figure 8 shows that further MM-induced bone loss is
Figure 2. The variation of normalized ratio of OBa:OCa with respect to its initial value during different
periods. Days 1 to 50: normal period; days 51 to 300: invasion of MM cells; and from day 301: intervention
with bisphosphonate therapy.
Figure 3. The variation of normalized bone volume with respect to its initial value during different periods.
Days 1 to 50: normal period; days 51 to 300: invasion of MM cells; and from day 301: intervention with
bisphosphonate therapy.
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prevented after a short period of ﬂuctuation through the intervention with bortezomib, while the
OBa:OCa ratio (shown in Figure 9) again undergoes a short period of ﬂuctuation and then returns
to a level similar to its original value without the myeloma cells. This explains the termination or
inhibition of MM-induced bone loss because of bortezomib.
Sensitivity of the simulations to the value of F.Bo is explored in Figures 10 to 12, which show the
variations in the output data with F.Bo values of 2.0, 2.2 and 2.4. Overall the simulations are not
particularly sensitive to this level of variation. MM cell population decreases to 86.4%, 86.2%
and 86.0%, bone volume decreases to 97.4%, 97.5% and 97.6% and OBa:OCa ratio increases
to 122.1%, 124.5% and 126.7%, respectively. In Figure 11, when F.Bo equals 2.0, MM-induced
bone loss continues although its rate is greatly reduced, because of the increased OBa:OCa ratio
(Figure 12). When F.Bo is 2.2 and greater, a near zero or positive bone balance is achieved after
the bortezomib therapy. The results suggest that the degree of reduction in MM cell viability and
mitigation of bone destruction are both positively related to the value of F.Bo.
Figure 4. The variation of normalized MM cell concentration with respect to the value at day 300 after use
of the bisphosphonates therapy with different values of F.Bi.
Figure 5. The variation of normalized ratio of OBa:OCa with respect to the value at day 300 after use of the
bisphosphonate therapy with different values of F.Bi.
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3.3. Simulation of TGF-β inhibition treatment
The variations in cell concentrations, bone volume and the ratio of OBa:OCa after the intervention
of TGF-β therapy (from day 301 with F.T set to 0.7) are presented in Figures 13 to 15. TGF-β sup-
pression leads to a decline in MM cell population and bone cell concentrations, with the reduction
of 13.0% in MM cell numbers (at day 450) suggesting that the tumour burden can be reduced
through the inhibitionof TGF-β. However, the MM-induced bone destruction actually increases af-
ter the TGF-β therapy (Figure 14). This increase in bone loss can be explained by the 18.7%
Figure 6. The variation of normalized bone volume with respect to its initial value after use of the bis-
phosphonate therapy with different values of F.Bi.
Figure 7. The variation of normalized cell concentrations with respect to their initial values during different
periods. Days 1 to 50: normal period; days 51 to 300: invasion of MM cells; and from day 301: intervention
with bortezomib therapy.
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decrease in OBa:OCa ratio, compared to the value at day 300, caused by the TGF-β therapy (as
shown in Figure 15).
Finally, Figures 16 and 17 show the variations in the output data with different values of F.T (of
0.7, 0.8 and 0.9). As a result, the population of MM cells decreases to 87.0%, 87.4% and 87.8%,
and the OBa:OCa ratio decreases to 81.3%, 89.6% and 97.41% of the normal value, respectively.
The decrease in the ratio of active osteoblasts to osteoclasts (observed with all applications of
TGF-β) leads to continued bone loss after treatment, with the lowest levels of TGF-β leading to
the greatest loss of bone volume (Figure 18).
Figure 8. The variation of normalized bone volume with respect to its initial value during different periods.
Days 1 to 50: normal period; days 51 to 300: invasion of MM cells; and from day 301: intervention with
bortezomib therapy.
Figure 9. The variation of normalized ratio of OBa:OCa with respect to its initial value during different
periods. Days 1 to 50: normal period; days 51 to 300: invasion of MM cells; and from day 301: intervention
with bortezomib therapy.
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4. DISCUSSION
In this paper, a mathematical model ﬁrst described in [3] was extended to simulate and evaluate
three different therapeutic approaches to manage MM-induced bone disease. Full details of the ba-
sic model and its validation are described in length in that publication, and are not repeated here.
The therapies investigated are: bisphosphonates, bortezomib and TGF-β inhibition, and their effects
on MM and bone cell populations and bone volume are considered.
Bisphosphonates are used widely in the management of MM-induced bone disease, and are able
to inhibit osteoclast activity and bone resorption. However, the degree to which it affects MM cell
viability and has an anti-tumour effect is not clear. The model simulation suggests that bisphospho-
nate therapy can not only suppress bone loss, but also reduce MM cell population. This is conﬁrmed
Figure 10. The variation of normalized MM cell concentration with respect to the value at day 300 after use
of the bortezomib therapy with different values of F.Bo.
Figure 11. The variation of normalized bone volume with respect to its initial value after use of the
bortezomib therapy with different values of F.Bo.
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by published data that reporting that bisphosphonates suppress MM-induced bone destruction [8,
9]. It is should be noted that direct anti-tumour effects from the bisphosphonate are not considered
in the model; thus, the decreased tumour burden is due solely to the inhibited osteoclast activity,
indicating that bisphosphonate therapy has an indirect anti-tumour effect. This ﬁnding agrees with
experimental observations that a decrease in osteoclast activity inhibits proliferation of MM cells [6,
26]. The underlying mechanism for the indirect effect of bisphosphonate treatment lies in the fact
that bisphosphonate therapy suppresses bone resorption, and thus results in a decrease in TGF-β
Figure 12. The variation of normalized ratio of OBa:OCa with respect to the value at day 300 after use of
the bortezomib therapy with different values of F.Bo.
Figure 13. The variation of normalized cell concentrations with respect to their initial values during dif-
ferent periods. Days 1 to 50: normal period; days 51 to 300: invasion of MM cells; and from day 301: in-
tervention with TGF-β therapy.
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release, which then inhibits the proliferation of MM cells by suppressing IL-6 secretion, because
IL-6 promotes the proliferation of MM cells [5, 8, 27, 28].
Osteoblast suppression occurring in MM patients facilitates the growth of MM cells and bone
loss; therefore, bortezomib, which can enhance osteoblast proliferation, is suggested as a potential
therapeutic intervention for MM. In its simulation here, bortezomib therapy is indeed shown to be
effective in the management of MM-induced bone disease through its action to decrease the viabil-
ity of MM cells while limiting MM-induced bone destruction. The inhibition of MM cells by the
bortezomib therapy agrees with the experimental ﬁnding that increased osteoblast proliferation is
Figure 14. The variation of normalized bone volume with respect to its initial value during different periods.
Days 1 to 50: normal period; days 51 to 300: invasion of MM cells; and from day 301: intervention with
TGF-β therapy.
Figure 15. The variation of normalized ratio of OBa:OCa with respect to its initial value during different
periods. Days 1 to 50: normal period; days 51 to 300: invasion of MM cells; and from day 301: intervention
with TGF-β therapy.
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able to reduce tumour burden in MM patients [23, 29, 30]. Thus, the stimulation of osteoblast ac-
tivity with therapies, such as bortezomib, can inhibit or even stop bone destruction as well as the
tumour burden, and is an effective therapy for MM patients.
Because TGF-β can indirectly promote the progression of MM cells, its inhibition is also
suggested as a possible treatment for MM-induced bone disease [5]. However, although the model
simulation indicates that this approach can lead to a decrease in MM cell viability, the MM-induced
bone loss is not inhibited and can become worse. In addition to the effect of TGF-β on osteoblasts,
TGF-β can also inhibit osteoclasts by promoting their apoptosis [31], and TGF-β inhibition would
unavoidably lead to an increase in osteoclast activity and resultant bone resorption. This explains
the increased bone loss resulting from TGF-β inhibition. Therefore the MM management through
inhibition of TGF-β treatment does not appear to be effective using our modelling techniques.
The relationships between the treatment parameters (F.Bi, F.Bo and F.T) and equivalent drug
dosages are currently not known; hence simulations to determine the sensitivity of the results to
the values have been undertaken. The different treatment options can be clearly seen to work in
Figure 16. The variation of normalized MM cell concentration with respect to the value at day 300 after use
of the TGF-β therapy with different values of F.T.
Figure 17. The variation of normalized ratio of OBa:OCa with respect to the value at day 300 after use of
the TGF-β therapy with different values of F.T.
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different ways, and notwithstanding the uncertainty in the parameter values, all three simulations
show qualitative agreement with the available clinical data, providing some degree of conﬁdence
in the model. Clearly further work and quantitative clinical data is required to conﬁrm the parameter
values and validate the model and its use in this application. Until then, it is hoped that this paper
can serve as a virtual evaluation tool, which can be used to suggest new therapies or combinations
of therapies and to explore the possible effectiveness of new therapeutic approaches before
embarking on expensive clinical trials.
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